J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Original Article

Volume 12, Number 2, February 2020, pages 73-78

Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial

Figure 2. Serum triglyceride and apolipoprotein B-48 levels by meal tolerance test before and after treatment. (a) Changes in triglyceride, and (b) changes in apolipoprotein B-48. # P < 0.05; ## P < 0.01 compared with baseline (0 week).

**Table 1.** Patient Characteristics
	Anagliptin group (n = 29)	Miglitol group (n = 23)	P
Sex ratio/distribution (men/women)	23/6	19/4	1.0000
Age (years)	53.7 ± 8.5	56.3 ± 8.4	0.2865
Duration of diabetes (years)	6.5 ± 7.9	3.6 ± 3.2	0.0789
Body weight (kg)	77.0 ± 17.1	75.6 ± 13.7
Height (cm)	165.6 ± 7.0	167.8 ± 8.1
Body mass index (kg/m²)	27.9 ± 4.6	26.8 ± 4.3

Table 1. Patient Characteristics

Anagliptin group (n = 29)

Miglitol group (n = 23)

Sex ratio/distribution (men/women)

23/6

19/4

1.0000

Age (years)

53.7 ± 8.5

56.3 ± 8.4

0.2865

Duration of diabetes (years)

6.5 ± 7.9

3.6 ± 3.2

0.0789

Body weight (kg)

77.0 ± 17.1

75.6 ± 13.7

Height (cm)

165.6 ± 7.0

167.8 ± 8.1

Body mass index (kg/m²)

27.9 ± 4.6

26.8 ± 4.3

**Table 2.** Comparison of Parameters Before and After Treatment With Anagliptin or Miglitol
	Anagliptin group (n = 29)	Miglitol group (n = 23)	P3
P1: comparison of changes between baseline and after 12 weeks in anagliptin group; P2: comparison of changes between baseline and after 12 weeks in miglitol group; and P3: comparison of each level between anagliptin group and miglitol group at 12 weeks. HbA1c: hemoglobin A1c; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; apoB-48: apolipoprotein B-48; apoB-100: apolipoprotein B-100; MDA-LDL-C: malondialdehyde-modified LDL-C; sd-LDL-C: small dense LDL-C.
Number	29		27		23		20
HbA1c (%)	7.9 ± 1.2	7.6 ± 1.3	7.2 ± 1.3	0.0000	8.0 ± 1.8	7.4 ± 1.3	7.3 ± 1.1	0.0068	0.0773
LDL-C (mg/dL)	153.8 ± 30.7	149.7 ± 24.5	147.6 ± 23.1	0.1897	148.1 ± 22.8	140.7 ± 19.6	150.3 ± 20.3	0.2114	0.1717
HDL-C (mg/dL)	53.4 ± 15.7	52.4 ± 16.0	51.8 ± 15.7	0.0216	59.0 ± 11.4	55.5 ± 12.7	55.9 ± 13.5	0.1821	0.7419
Non HDL-C (mg/dL)	176.8 ± 35.4	171.1 ± 27.2	169.6 ± 25.1	0.0165	170.0 ± 25.5	159.2 ± 20.5	170.5 ± 22.2	0.5668	0.2869
TC (mg/dL)	230.2 ± 40.0	223.6 ± 30.1	221.4 ± 31.2	0.0929	229.0 ± 29.3	214.8 ± 26.4	226.4 ± 28.1	0.9349	0.1899
TG (mg/dL)	154.2 ± 92.4	146.4 ± 78.5	152.0 ± 72.1	0.8439	153.6 ± 63.0	140.7 ± 46.4	145.0 ± 59.9	0.3754	0.4892
ApoB-48 (µg/mL)	3.8 ± 4.1	-	4.2 ± 3.4	0.3900	5.0 ± 7.1	-	5.1 ± 4.5	0.9585	0.7369
ApoB-100 (µg/mL)	4.3 ± 1.1	-	4.3 ± 1.1	0.6403	4.4 ± 1.0	-	4.2 ± 0.9	0.2579	0.5828
Sd-LDL-C (mg/dL)	56.6 ± 21.9	-	49.2 ± 14.8	0.0510	55.6 ± 18.0	-	53.5 ± 18.7	0.4529	0.2632
MDA-LDL-C (U/L)	164.1 ± 38.6	-	152.3 ± 34.7	0.1046	166.2 ± 41.2	-	173.3 ± 82.3	0.5829	0.1075
Lathosterol (µg/mL)	3.2 ± 1.3	-	3.1 ± 1.2	0.7182	3.4 ± 1.2	-	3.1 ± 1.3	0.0599	0.4334
Campesterol (µg/mL)	4.1 ± 1.7	-	4.5 ± 1.9	0.2177	4.1 ± 2.1	-	4.4 ± 2.6	0.0407	0.4254
Sitosterol (µg/mL)	2.2 ± 0.9	-	2.4 ± 1.0	0.1365	2.1 ± 1.0	-	2.4 ± 1.3	0.0441	0.3156
Cholestanol (µg/mL)	2.5 ± 0.8	-	2.5 ± 0.8	0.6713	2.4 ± 0.5	-	2.5 ± 0.6	0.1513	0.7512

Table 2. Comparison of Parameters Before and After Treatment With Anagliptin or Miglitol

Anagliptin group (n = 29)

Miglitol group (n = 23)

Baseline

4 weeks

12 weeks

Baseline

4 weeks

12 weeks

P1: comparison of changes between baseline and after 12 weeks in anagliptin group; P2: comparison of changes between baseline and after 12 weeks in miglitol group; and P3: comparison of each level between anagliptin group and miglitol group at 12 weeks. HbA1c: hemoglobin A1c; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; apoB-48: apolipoprotein B-48; apoB-100: apolipoprotein B-100; MDA-LDL-C: malondialdehyde-modified LDL-C; sd-LDL-C: small dense LDL-C.

Number

HbA1c (%)

7.9 ± 1.2

7.6 ± 1.3

7.2 ± 1.3

0.0000

8.0 ± 1.8

7.4 ± 1.3

7.3 ± 1.1

0.0068

0.0773

LDL-C (mg/dL)

153.8 ± 30.7

149.7 ± 24.5

147.6 ± 23.1

0.1897

148.1 ± 22.8

140.7 ± 19.6

150.3 ± 20.3

0.2114

0.1717

HDL-C (mg/dL)

53.4 ± 15.7

52.4 ± 16.0

51.8 ± 15.7

0.0216

59.0 ± 11.4

55.5 ± 12.7

55.9 ± 13.5

0.1821

0.7419

Non HDL-C (mg/dL)

176.8 ± 35.4

171.1 ± 27.2

169.6 ± 25.1

0.0165

170.0 ± 25.5

159.2 ± 20.5

170.5 ± 22.2

0.5668

0.2869

TC (mg/dL)

230.2 ± 40.0

223.6 ± 30.1

221.4 ± 31.2

0.0929

229.0 ± 29.3

214.8 ± 26.4

226.4 ± 28.1

0.9349

0.1899

TG (mg/dL)

154.2 ± 92.4

146.4 ± 78.5

152.0 ± 72.1

0.8439

153.6 ± 63.0

140.7 ± 46.4

145.0 ± 59.9

0.3754

0.4892

ApoB-48 (µg/mL)

3.8 ± 4.1

4.2 ± 3.4

0.3900

5.0 ± 7.1

5.1 ± 4.5

0.9585

0.7369

ApoB-100 (µg/mL)

4.3 ± 1.1

0.6403

4.4 ± 1.0

4.2 ± 0.9

0.2579

0.5828

Sd-LDL-C (mg/dL)

56.6 ± 21.9

49.2 ± 14.8

0.0510

55.6 ± 18.0

53.5 ± 18.7

0.4529

0.2632

MDA-LDL-C (U/L)

164.1 ± 38.6

152.3 ± 34.7

0.1046

166.2 ± 41.2

173.3 ± 82.3

0.5829

0.1075

Lathosterol (µg/mL)

3.2 ± 1.3

3.1 ± 1.2

0.7182

3.4 ± 1.2

3.1 ± 1.3

0.0599

0.4334

Campesterol (µg/mL)

4.1 ± 1.7

4.5 ± 1.9

0.2177

4.1 ± 2.1

4.4 ± 2.6

0.0407

0.4254

Sitosterol (µg/mL)

2.2 ± 0.9

2.4 ± 1.0

0.1365

2.1 ± 1.0

2.4 ± 1.3

0.0441

0.3156

Cholestanol (µg/mL)

2.5 ± 0.8

0.6713

2.4 ± 0.5

2.5 ± 0.6

0.1513

0.7512

**Table 3.** Adverse Effects
Adverse effects	Anagliptin group	Miglitol group
Values are n.
Gastrointestinal symptoms	3	15
Drug eruption	1
Liver dysfunction	1
Weight loss		2

Table 3. Adverse Effects

Adverse effects

Anagliptin group

Miglitol group

Values are n.

Gastrointestinal symptoms

Drug eruption

Liver dysfunction

Weight loss

**Table 4.** Medication Adherence
Medication adherence	Anagliptin group	Miglitol group	P
Percentage forgetting to take oral medication	1.58 ± 3.46	3.36 ± 4.59	0.1184

Table 4. Medication Adherence

Medication adherence

Anagliptin group

Miglitol group

Percentage forgetting to take oral medication

1.58 ± 3.46

3.36 ± 4.59

0.1184